Trial reportJournal of translational medicine2013
Functional effect of Saffron supplementation and risk genotypes in early age-related macular degeneration: a preliminary report.
Trial report in Journal of translational medicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 2 syntheses or guidelines pooled it, 67 citations in OpenAlex.
- Pharmacological Effects of Saffron and its Constituents in Ocular Disorders from in vitro Studies to Clinical Trials: A Systematic Review.Current neuropharmacology · 2021Pooled it
- A systematic review of randomized controlled trials examining the effectiveness of saffron (Crocus sativus L.) on psychological and behavioral outcomes.Journal of integrative medicine · 2015Pooled it
- An Open-Label Pilot Study on Macumax Supplementation for Dry-Type Age-Related Macular Degeneration.Journal of medicinal food · 2021Trial
- Saffron as a Retinal Neuroprotectant: A Narrative Review of Preclinical Studies and Clinical Results.Antioxidants (Basel, Switzerland) · 2026Review
- Plant-Based Care and Therapy in Ophthalmology.Antioxidants (Basel, Switzerland) · 2025Review
- Regulated cell death in age-related macular degeneration: Regulatory mechanisms and therapeutic potential.Journal of pharmaceutical analysis · 2025Review
- Natural products for the treatment of age-related macular degeneration: New insights focusing on mitochondrial quality control and cGAS/STING pathway.Journal of pharmaceutical analysis · 2025Review
- Harnessing Nature's Bounty: The Neuroprotective Potential of Phytoconstituents and Nanotechnology in Neurodegenerative Disease Therapeutics.CNS & neurological disorders drug targets · 2025Review
- Different Therapeutic Approaches for Dry and Wet AMD.International journal of molecular sciences · 2024Review
- The Role of Oral Supplementation for the Management of Age-Related Macular Degeneration: A Narrative Review.Journal of personalized medicine · 2024Review
- Medicinal Plant-derived Phytochemicals in Detoxification.Current pharmaceutical design · 2024Review
- Perspectives of traditional herbal medicines in treating retinitis pigmentosa.Frontiers in medicine · 2024Article
- Review
- A Window to the Brain: The Retina to Monitor the Progression and Efficacy of Saffron RepronPharmaceuticals (Basel, Switzerland) · 2023Article
- Saffron and retinal neurodegenerative diseases: Relevance of chemical composition.Journal of anatomy · 2023Article
- Polyunsaturated Lipids in the Light-Exposed and Prooxidant Retinal Environment.Antioxidants (Basel, Switzerland) · 2023Review
- Saffron, Its Active Components, and Their Association with DNA and Histone Modification: A Narrative Review of Current Knowledge.Nutrients · 2022Review
- Saffron and its active ingredients against human disorders: A literature review on existing clinical evidence.Iranian journal of basic medical sciences · 2022Review
- Dietary supplements in retinal diseases, glaucoma, and other ocular conditions.Journal of preventive medicine and hygiene · 2022Review
- Discovering the Potential of Natural Antioxidants in Age-Related Macular Degeneration: A Review.Pharmaceuticals (Basel, Switzerland) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo determine whether the functional effects of oral supplementation with Saffron, a natural compound that proved to be neuroprotective in early age-related macular degeneration, are influenced by complement factor H (CFH) and age-related maculopathy susceptibility 2 (ARMS2) risk genotypes.
methodsThirty-three early AMD patients, screened for CFH (rs1061170) and ARMS2 (rs10490924) polymorphisms and receiving Saffron oral supplementation (20 mg/day) over an average period of treatment of 11 months (range, 6-12), were longitudinally evaluated by clinical examination and focal electroretinogram (fERG)-derived macular (18°) flicker sensitivity estimate. fERG amplitude and macular sensitivity, the reciprocal value of the estimated fERG amplitude threshold, were the main outcome measures.
resultsAfter three months of supplementation, mean fERG amplitude and fERG sensitivity improved significantly when compared to baseline values (p < 0.01). These changes were stable throughout the follow-up period. No significant differences in clinical and fERG improvements were observed across different CFH or ARMS2 genotypes.
conclusionsThe present results indicate that the functional effect of Saffron supplementation in individual AMD patients is not related to the major risk genotypes of disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.